Gynecologic oncology最新文献

{"title":"All-cause mortality and neighborhood social vulnerability among women with ovarian cancer","authors":"Austin Hicks ,&nbsp;Lauren Borho ,&nbsp;Esther Elishaev ,&nbsp;Jessica Berger ,&nbsp;Michelle Boisen ,&nbsp;John Comerci ,&nbsp;Madeleine Courtney-Brooks ,&nbsp;Robert P. Edwards ,&nbsp;Alison Aunkst Garrett ,&nbsp;Joseph L. Kelley ,&nbsp;Jamie Lesnock ,&nbsp;Haider S. Mahdi ,&nbsp;Alexander Olawaiye ,&nbsp;Shannon Rush ,&nbsp;Paniti Sukumvanich ,&nbsp;Sarah Taylor ,&nbsp;Francesmary Modugno","doi":"10.1016/j.ygyno.2025.02.014","DOIUrl":"10.1016/j.ygyno.2025.02.014","url":null,"abstract":"<div><h3>Objective</h3><div>Neighborhood-level social determinants of health (<strong>N</strong>-<strong>SDoH</strong>) impact cancer survival. However, the relationship between N-SDoH and epithelial ovarian cancer (<strong>EOC</strong>) survival remains understudied.</div></div><div><h3>Methods</h3><div>We used data on all Pennsylvania residents diagnosed with EOC from 2000 to 2023 throughout the University of Pittsburgh Medical Center to assess the impact of N-SDoH on survival. We used the Social Vulnerability Index (<strong>SVI)</strong> to characterize four N-SDoH themes and overall N-SDoH vulnerability based on each case's census tract at diagnosis. High-SVI overall and by N-SDoH theme was defined as being in the 75th percentile in Pennsylvania for that metric. Cox proportional hazard models assessed the association between high-SVI and overall mortality.</div></div><div><h3>Results</h3><div>Among 4970 EOC cases, high-SVI overall was associated with later stage at diagnosis, greater residual disease, and a lower likelihood of receiving standard-of-care platinum-based therapy. High-SVI was also associated with a 13 % increased mortality hazard (adjusted-HR:1.13 95 %CI:1.02–1.25). The Household Characteristics, Racial and Ethnic Minority Status, and Housing Type and Transportation themes were also associated with increased mortality hazards (adjusted-HR[95 %CI]: 1.10[1.01–1.21], 1.23[1.08–1.39], 1.09[1.00–1.18], respectively). The Socioeconomic Status theme was associated with an increased mortality hazard of borderline significance (adjusted-HR 1.10, 95 %CI:0.99–1.23). The overall high-SVI association appeared similar when stratifying by race, although the number of Black cases was small (<em>n</em> = 168).</div></div><div><h3>Conclusion</h3><div>Higher neighborhood social vulnerability is associated with worse EOC survival. Replicating study findings in more diverse populations can help illuminate the neighborhood factors most influencing survival and support the design and testing of programs to reduce poor EOC outcome, especially within marginalized communities.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"195 ","pages":"Pages 26-33"},"PeriodicalIF":4.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery","authors":"Claudia Marchetti ,&nbsp;Raffaella Ergasti ,&nbsp;Filippo Maria Capomacchia ,&nbsp;Diana Giannarelli ,&nbsp;Luca Mastrantoni ,&nbsp;Francesco Pepe ,&nbsp;Adriana Ionelia Apostol ,&nbsp;Carolina Maria Sassu ,&nbsp;Camilla Nero ,&nbsp;Alessia Piermattei ,&nbsp;Gian Franco Zannoni ,&nbsp;Giancarlo Troncone ,&nbsp;Olivier Colomban ,&nbsp;Gianluca Russo ,&nbsp;Aurore Carrot ,&nbsp;Umberto Malapelle ,&nbsp;Benoit You ,&nbsp;Domenica Lorusso ,&nbsp;Giovanni Scambia ,&nbsp;Anna Fagotti","doi":"10.1016/j.ygyno.2025.02.016","DOIUrl":"10.1016/j.ygyno.2025.02.016","url":null,"abstract":"<div><h3>Objective</h3><div>Selecting the maintenance strategy for advanced tubo-ovarian high-grade serous carcinoma (HGSC) is challenging. This study evaluates the correlation among chemotherapy response score (CRS), homologous recombination deficiency (HRD) status, and KELIM score; identifies predictors of Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) efficacy and stratifies recurrence risk in PARPi-treated population.</div></div><div><h3>Methods</h3><div>Median Progression-free Survival (mPFS) and hazard ratios (HRs) were retrospectively calculated in HGSC patients after neoadjuvant chemotherapy (3/4 cycles), interval cytoreductive surgery, and adjuvant treatment. Variables included HRD status, disease stage, KELIM, radiological response, residual tumor, and CRS at surgery. A risk-stratification model predicting PARPi efficacy was developed.</div></div><div><h3>Results</h3><div>Among overall population (<em>N</em> = 373), 66.9 % of CRS3 patients reached favorable KELIM, 17.3 % had complete radiological response, and 97.8 % achieved complete surgery, with higher frequencies than CRS1/2 (<em>p</em> &lt; 0.001). Univariate analysis of PFS on PARPi (<em>N</em> = 210) showed favorable covariates: CRS3 (HR 2.37, 95 % CI 1.39–4.04 and HR 1.59, 95 % CI 1.03–2.47 vs CRS1 and CRS2), BRCA mutation (HR 3.41 95 % CI 2.15–5.39 and HR 2.00 95 % CI 1.13–3.56 vs BRCAwt-HRDneg and -HRDpos) and continuum KELIM (HR 0.66, 95 % CI 0.45–0.96). At multivariate, CRS3 and BRCA mutation were confirmed significant. Combining HRD status, CRS, and KELIM four prognostic groups with different PARPi efficacy were identified (mPFS 38 vs 26 vs 18 vs 6 months for Low, Intermediate, High-Intermediate, and High-risk groups).</div></div><div><h3>Conclusions</h3><div>CRS is a prognostic factor in PARPi-treated population as a PARPi efficacy surrogate. Integrating HRD status, CRS, and KELIM allows patients risk stratification and tailored maintenance. These results should be considered hypothesis-generating.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"195 ","pages":"Pages 16-25"},"PeriodicalIF":4.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy","authors":"Giovanni Fucà ,&nbsp;Cristian Dell'Acqua ,&nbsp;Beatrice Peruffo ,&nbsp;Gloria Lalli ,&nbsp;Ilaria Sabatucci ,&nbsp;Mariachiara Paderno ,&nbsp;Giampaolo Di Martino ,&nbsp;Mauro Signorelli ,&nbsp;Matteo Maruccio ,&nbsp;Fabio Martinelli ,&nbsp;Domenica Lorusso","doi":"10.1016/j.ygyno.2025.02.021","DOIUrl":"10.1016/j.ygyno.2025.02.021","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"195 ","pages":"Pages 12-15"},"PeriodicalIF":4.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Signal transduction pathway activity in adult-type granulosa cell tumor samples","authors":"G.J. Brink ,&nbsp;J.W. Groeneweg ,&nbsp;P. van der Ploeg ,&nbsp;G.N. Jonges ,&nbsp;E.H. Gort ,&nbsp;P.O. Witteveen ,&nbsp;R.P. Zweemer ,&nbsp;J.M.J. Piek","doi":"10.1016/j.ygyno.2025.02.018","DOIUrl":"10.1016/j.ygyno.2025.02.018","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to evaluate signal transduction pathway (STP) activity in adult-type granulosa cell tumors (aGCT) in order to identify potential therapeutic targets. These results are compared with STP activity in healthy ovarian tissue and low and high grade serous ovarian carcinoma (LGSC and HGSC).</div></div><div><h3>Methods</h3><div>STP activity was assessed by a RNA-based assay for the following oncogenic pathways: Hedhehog (HH), transforming growth factor beta (TGF-β), Notch, phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), androgen receptor (AR) and estrogen receptor (ER).</div></div><div><h3>Results</h3><div>Samples of 31 aGCTs and a healthy granulosa cell were included and compared with 24 LGSC and 50 HGSC samples. In aGCT, significantly higher activity of the HH, Notch, PI3K and ER pathways was found, as compared to healthy granulosa cells. When compared with LGSC and HGSC, aGCT exhibited significantly higher PI3K pathway activity and lower HH, TGF-β, Notch, MAPK, AR, and ER pathway activity.</div></div><div><h3>Conclusions</h3><div>Our results show high PI3K pathway activity in aGCT samples. Pathway activity contrasts with findings in both healthy granulosa cells and serous ovarian carcinoma. Therefore, the PI3K pathway may be a target for treatment, specifically for aGCT patients.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"195 ","pages":"Pages 6-11"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok","authors":"Jessica Velasquez,&nbsp;Maryam Mohammed-Norgan,&nbsp;Alexandra Scheiber,&nbsp;Julia Chalif,&nbsp;Anna Gonzalez,&nbsp;Danielle Glassman,&nbsp;Molly Morton,&nbsp;David M. O'Malley,&nbsp;Laura M. Chambers","doi":"10.1016/j.ygyno.2025.02.004","DOIUrl":"10.1016/j.ygyno.2025.02.004","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate themes, quality, and reliability of cervical cancer (CC) related Spanish-language content on TikTok as compared to English-language content.</div></div><div><h3>Methods</h3><div>TikTok was systematically searched for the top 200 Spanish-language and 100 English-language posts for CC in August 2024. Data were collected including creator demographics, timing of posts in relation to diagnosis, tone, intent, and themes. The modified DISCERN, a validated tool including structured questions assessing reliability and of health-related resources was utilized to assess videos with educational intent. Differences were assessed.</div></div><div><h3>Results</h3><div>There were more physician Spanish-language creators (27.8 %) compared to physician English-language creators (11.00 %, <em>p</em> &lt; 0.001). Most Spanish-language education videos were created by physicians (82.25 %). Spanish-language posts were more likely to feature themes of treatment toxicities (7.5 % vs 1.7 %, <em>p</em> &lt; 0.001), faith (3.7 % vs 0.7 %, <em>p</em> = 0.003), pain (2.0 % vs 0 %, <em>p</em> = 0.001), family support (1.6 % vs 0 %, <em>p</em> = 0.004), hair loss (1.8 % vs 0.3 %, <em>p</em> = 0.039), and long-term treatment sequelae (1.4 % vs 0 %, <em>p</em> = 0.007); and less likely to address themes of diagnosis (11.8 % vs 18.0 %, <em>p</em> &lt; 0.001), fear or anxiety about cancer (3.4 % vs 8.2 %, <em>p</em> = 0.002), impact on sexual function (0.6 % vs 6.1 %, <em>p</em> &lt; 0.001) and parenthood (0 % vs 3.7 %, p &lt; 0.001). The median DISCERN score was 1.42 (Interquartile Range [IQR] 1.33–1.67) and 1.33 (IQR 1.00–1.92), for Spanish and English-language posts, respectively (<em>p</em> = 0.385).</div></div><div><h3>Conclusions</h3><div>There were significantly more Spanish-language physician creators suggesting a strong interest in physician-driven content. Thematic differences between Spanish-language and English-language posts highlight important differences in experiences. CC-related content is of poor educational quality, regardless of language. Improving TikTok educational content could increase CC awareness and prevention.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages 131-136"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists","authors":"Inés Debbiche ,&nbsp;Connor C. Wang ,&nbsp;Maria Gomez-Roas ,&nbsp;Olivia W. Foley ,&nbsp;Allison Grubbs ,&nbsp;Emma L. Barber","doi":"10.1016/j.ygyno.2025.01.007","DOIUrl":"10.1016/j.ygyno.2025.01.007","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the relationship between preoperative sleep efficiency (percentage of time asleep while in bed) and postoperative outcomes in gynecologic oncology patients.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of a prospective cohort study that included 90 patients undergoing gynecologic surgeries from March 2021 to November 2023. Preoperative sleep efficiency was measured via Oura rings over the seven days prior to surgery and analyzed as a continuous variable and in quartiles. Primary outcomes were 30-day postoperative complications, with secondary outcomes including total morphine milligram equivalents (MME) prescribed at discharge and pain scores on postoperative day 1 (POD1). Multivariable analyses controlled for age, body mass index, frailty status, neoadjuvant chemotherapy, use of preoperative sleep medications, and surgical approach.</div></div><div><h3>Results</h3><div>Higher preoperative sleep efficiency was independently associated with fewer 30-day postoperative complications. On multivariable analysis, each 1 % increase in sleep efficiency was associated with 6 % lower adjusted odds of complications. (aOR: 0.94; 95 % CI: 0.89–0.996) and significantly lower total MME prescribed at discharge (β = −13.94; 95 % CI: −19.35 to −8.53). Patients in the highest sleep efficiency quartile (&gt;89.0 %) had lower odds of experiencing a complication compared to those in the lowest quartile (aOR: 0.28; 95 % CI: 0.09–0.92). Sleep efficiency was not significantly associated with POD1 pain scores (β = −0.06; 95 % CI: −0.13 to 0.01).</div></div><div><h3>Conclusion</h3><div>Preoperative sleep efficiency is associated with fewer postoperative complications and lower MME prescribed at discharge. This may be modifiable risk factor to improve recovery and outcomes.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages 119-124"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024","authors":"Kaitlyn G. Dinkins ,&nbsp;Grace M. Lee ,&nbsp;Rebecca C. Arend ,&nbsp;Charles A. Leath III ,&nbsp;Michael D. Toboni","doi":"10.1016/j.ygyno.2025.03.010","DOIUrl":"10.1016/j.ygyno.2025.03.010","url":null,"abstract":"<div><h3>Objective</h3><div>To quantify the impact of Food and Drug Administration (FDA) therapeutic approvals in gynecologic oncology from 2019 to 2024 and compare these approvals to other solid tumor disease sites.</div></div><div><h3>Methods</h3><div>The FDA Approval Notifications was evaluated to assess drug approvals for solid tumors between August 15, 2019 and August 15, 2024. Drug approvals were evaluated to determine if they replaced the current standard of care (SOC), were used in combination with currently approved drugs, were used for adjuvant or maintenance therapy, or were approved for recurrence. Average therapeutic approval growth for each solid tumor category was calculated using the slope (b) from a simple linear regression model. Statistics were performed via Prism v10.1.1.</div></div><div><h3>Results</h3><div>There were 150 drug approvals for solid tumors with gynecologic cancers representing 9.3 %. Gynecologic oncology had the second highest number of drug approvals compared to all other solid tumor disease sites. Of these, 8 were add on therapies (57.1 %) and 6 were later line therapies (42.9 %). Most disease sites (61.0 %) experienced an average decrease in FDA drug approvals during the study period. However, gynecologic oncology had the third largest approval growth (b = 0.17) compared to all other solid tumors.</div></div><div><h3>Conclusion</h3><div>While only representing 5 % of the oncology field, gynecologic oncology held the second highest number of FDA approvals by disease site in solid tumors (Ackroyd et al., 2021 [<span><span>1</span></span>]). The add on therapies provide a significant benefit in progression free and overall survival in the frontline setting and the later line therapies offer promising response rates in a heavily pre-treated population. This study highlights the promising future of gynecologic oncology therapeutics given the third largest relative growth in drug approvals compared to all other solid tumors.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages 153-158"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor","authors":"Jian Li ,&nbsp;Thomas Welte ,&nbsp;Katherine Calzoncinth ,&nbsp;Veena K. Vuttaradhi ,&nbsp;Allison L. Brodsky ,&nbsp;Kwong-Kwok Wong ,&nbsp;Manu M. Sebastian ,&nbsp;Barrett Lawson ,&nbsp;Charles V. Kingsley ,&nbsp;R. Tyler Hillman","doi":"10.1016/j.ygyno.2025.01.011","DOIUrl":"10.1016/j.ygyno.2025.01.011","url":null,"abstract":"<div><h3>Background</h3><div>Adult-type granulosa cell tumors (AGCTs) are rare ovarian sex cord/stromal tumors with near-universal hotspot mutations in <em>FOXL2</em> (c.C402G; p.Cys134Trp). Progress in the treatment of relapsed AGCT has been hindered by the lack of high-fidelity <em>FOXL2</em>-based mouse models. To address this critical unmet need, we created and validated a genetically engineered inducible mouse model of the human <em>FOXL2</em> mutation that recapitulates the key features of the human disease.</div></div><div><h3>Methods</h3><div>Gene targeting in embryonic stem cells was used to introduce a Cre-inducible <em>Foxl2</em>^{<em>C130W</em>} allele (mouse equivalent of the human oncogenic mutation) into the endogenous mouse <em>Foxl2</em> locus. Animals with the <em>Foxl2</em>^{<em>C130W-FLEx</em>} allele were crossed with those carrying a well characterized <em>Amhr2-Cre</em> allele to achieve perinatal recombination in granulosa cells. Small animal magnetic resonance imaging (MRI) was used to monitor for tumor growth. Ovarian tumors were characterized using immunohistochemistry interpreted by veterinary and clinical gynecologic oncology pathologists.</div></div><div><h3>Results</h3><div>Female <em>Amhr2-Cre; Foxl2</em>^{<em>+/C130W-FLEx</em>} animals developed normally into adulthood. By 10 months of age, all eight <em>Amhr2-Cre; Foxl2</em>^{<em>+/C130W-FLEx</em>} females that were imaged by MRI exhibited cystic uterine changes. By 12–14 months of age, three <em>Amhr2-Cre; Foxl2</em>^{<em>+/C130W-FLEx</em>} females developed unilateral granulosa cell tumors ranging from microscopic to grossly visible size. The morphology and immunophenotype were consistent with human AGCT, as FOXL2, SF1 and Inhibin alpha were positive in all tumor cells.</div></div><div><h3>Conclusions</h3><div>A <em>Amhr2-Cre; Foxl2</em>^{<em>+/C130W-FLEx</em>} mouse model recapitulates key aspects of the human AGCT including a dependence upon the causative <em>FOXL2</em> mutation, concomitant uterine hyperplasia, and an age-dependent onset of tumors at the time of decreasing ovarian function. This new resource will accelerate translational research and therapeutic discovery for relapsed AGCT.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages 125-130"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?","authors":"Ramez N. Eskander","doi":"10.1016/j.ygyno.2025.03.026","DOIUrl":"10.1016/j.ygyno.2025.03.026","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages A3-A4"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity)","authors":"Lari Wenzel ,&nbsp;Chelsea McKinney ,&nbsp;Sally Jensen ,&nbsp;Devin Peipert ,&nbsp;Shaili Ganatra ,&nbsp;Jason Bredle ,&nbsp;Rachel Sisodia ,&nbsp;Kemi M. Doll ,&nbsp;Lauren Philp ,&nbsp;Rebecca Arend ,&nbsp;Jhalak Dholakia ,&nbsp;David Cella","doi":"10.1016/j.ygyno.2025.02.020","DOIUrl":"10.1016/j.ygyno.2025.02.020","url":null,"abstract":"<div><h3>Objectives</h3><div>The Society of Gynecologic Oncology (SGO) PROMOTE Study examined the content relevance of the FACT-Endometrial (FACT-En) measure to develop an updated measure that reflects priority symptoms/concerns among diverse endometrial cancer survivors.</div></div><div><h3>Methods</h3><div>Endometrial cancer patients diagnosed within the past 3 years were recruited through multiple platforms. Concept elicitation was conducted to identify priority symptoms/concerns to generate a symptom index, FACT-Endometrial Symptom Index (FEnSI). Participants listed 10 symptoms/concerns they considered most important during their cancer treatment, then rated the importance of each symptom/concern. Cognitive debriefing interviews assessed whether survey items were understood. Online surveys were administered and psychometric analyses were conducted to assess reliability and validity.</div></div><div><h3>Results</h3><div>Participants (16 White/Other; 15 Black) reported 49 symptoms/concerns along with a 0–10 importance rating. Responses from 66 participants (65 % White/other; 35 % Black) produced the following scales: Disease Related Symptoms – Physical (DRS<img>P, 8 items) (Crohnbach's alpha 0.78); Disease Related Symptoms – Emotional (DRS-E, 2 items) (0.46); Function/Wellbeing (F/WB, 4 items) (0.73); and Treatment Side Effects (TSE, 9 items, unscored). A Total index score was generated by summing responses to all 23 items. The scales demonstrated construct validity by distinguishing between clinical groups known to differ; the DRS<img>P, F/WB, and Total scores significantly differed across ECOG Performance Status categories (<em>p</em> &lt; 0.05), with large effect sizes (Cohen's d &gt; 0.80). Construct validity was demonstrated with moderate to large (&gt;0.371) correlations with scales from the FACT-En.</div></div><div><h3>Conclusion</h3><div>The FEnSI is a clinically meaningful patient-reported symptom index reflecting the symptoms/concerns identified as most important by diverse patients with endometrial cancer.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"194 ","pages":"Pages 137-144"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}